Clinical Study Of Ultrasound-guided Core Needle Biopsy In Breast Disease Diagnosis

Background:Breast cancer is one of common malignant tumors in women, and10%of the patients have breast cancer in the increasing number of patients who have cancer. Early diagnosis is the important methods to improve breast cancer survival rates, locally advanced breast cancer patients requires accurate pathological diagnosis for preoperative neoadjuvant chemotherapy,neoadjuvant endocrine therapy,so early diagnosis of breast cancer and standardized treatment become research hotspot now. Along with the medical technology progress and pathological diagnosis level enhancement, core needle biopsy has gradually replaced surgery pathology,study the tumor histological diagnosis coincidence rate of the specimen and immunohistochemical detection results between core needle biopsy and postoperative surgical resection can provide theoretical basis of neoadjuvant chemotherapy for breast cancer and neoadjuvant endocrine therapy,make sure personalized treatment.Objective:This paper aims to discuss the clinical value of ultrasound-guided core needle biopsy, and contrast the consistency of core needle biopsy specimen and surgical resection specimen pathological diagnosis consistency and immunohistochemical results consistency.Preoperative understanding of breast cancer patients with malignant degree and proliferation condition,can prepare well for lumpectomy surgery and sentinel lymph biopsy,and can provide important reference index for breast cancer patients with neoadjuvant chemotherapy,neoadjuvant endocrine therapy,thus to give them specific individual treatment, to increase the clinical cure rate, to increase the opportunity to do BCS (breast-conserving surgery),and to evaluate prognosis of breast cancer patients.Methods:92cases with breast tumors are taken ultrasound-guided core needle biopsy, analyzes the diagnosis consistency with surgery resection, so does positive predictive value, negative predictive value, specificity, sensitivity, false negative rate, underestimate rate, and we do immunohistochemical detection about ER, PR,Her-2and Ki-67on whom diagnosed with breast cancer, then we compare with the immunohistochemistry of postoperative pathologic results, and analyzes its diagnostic value.Results:We are satisfied with all92cases of breast tumor pathologic materials under ultrasound-guided Bard automatic biopsy gun.57cases are invasive intraducta carcinoma,3cases are intraductal carcinoma and postoperative pathology were proved to be intraductal carcinoma with tiny infiltration.32cases are benign, among them1cases of surgical pathology confirmed to false negative, no false positive results. The CNB Positive accuracy is98.91%,sensitivity to malignant breast tumor is98.36%, specificity is100%, positive predictive value is100%,negative predictive value is96.97%, false negative rate is3.125%, underestimate rate is4.918%.Contrast Core needle biopsy of ER, PR, Her-2,Ki-67with surgical resection pathological results, they have no statistically significant difference in the expression consistency (p>0.05),and have no statistically significant difference in the expression strength consistency (p>0.05).Conclusion:Ultrasound-guided core needle biopsy has the advances with less injury, easier operation, higher diagnosis accuracy, can replace the main pathological diagnosis results. Preoperative core needle biopsy of ER, PR, Her-2,Ki-67can be accurate reflect the main pathological immunohistochemical detection results, and can provide necessary reference index for neoadjuvant chemotherapy, neoadjuvant endocrine therapy and more choices of operations for breast cancer patients.